A Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination With ACP-319 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Trial Profile

A Multicenter, Open-label, Phase 1 Pilot Study of ACP-196 in Combination With ACP-319 in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 07 Dec 2016

At a glance

  • Drugs Acalabrutinib (Primary) ; ACP 319 (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Acerta Pharma
  • Most Recent Events

    • 06 Nov 2015 Planned primary completion date changed from 1 Aug 2017 to 1 Sep 2018 as reported by ClinicalTrials.gov record.
    • 06 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov record
    • 31 Mar 2015 Planned number of patients changed from 12 to 48 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top